In the absence of long-term data assessment in COVID-19, the various anti-inflammatory and beneficial systemic effects of SGLT2 inhibitors might contribute to playing a promising adjunctive therapy in LCS patients suffering from ongoing systemic inflammation. The gene discussed is SLC5A2; the disease is COVID-19.